#United States #Chicago #Riverain Technologies #CT scans #coronary artery calcification

Advancing Cardiac Risk Assessment with Riverain Technologies

In a significant leap for medical imaging technology, Riverain Technologies has unveiled its new ClearRead CT Coronary Artery Calcification (CAC) scoring system, enhancing ungated chest CT scans at the Radiological Society of North America’s annual meeting held from December 1-5, 2024, in Chicago. This innovative solution aims to tackle the critical health issue of coronary artery calcification that affects approximately 20 million Americans each year. More concerning is the fact that over half of the incidental findings related to CAC remain unreported, highlighting the need for effective detection methods.

The Importance of CAC Scoring

This newly developed technology allows healthcare providers to generate a CAC score to better assess the risk for heart disease with every ungated, non-contrast chest CT scan. Historically, specialized CT scans were the only method for evaluating coronary artery calcium, often restricted to symptomatic patients. This left many individuals at risk for delayed diagnoses and treatment. With ClearRead CT CAC, the opportunity for early diagnosis and treatment is broadened for a wider patient population. Steve Worrell, CEO of Riverain Technologies, emphasized, "With more than 4 million imaging exams processed annually using ClearRead solutions, there is a huge opportunity to improve patient health by maximizing the findings in each scan."

How ClearRead Works

Utilizing state-of-the-art machine learning and artificial intelligence, ClearRead CT CAC ensures consistent imaging results across various devices and demographics. The software employs unique suppression technology, known as Clear Visual Intelligence™, which filters out noise and irrelevant structures in the chest, such as bones and blood vessels. This clarity allows radiologists to focus on actionable data, leading to more precise detection, characterization, and reporting of health findings.

The incorporation of CAC scoring into the ClearRead suite marks a vital enhancement of existing nodule detection tools, enabling healthcare providers to make informed decisions based on better visual diagnostics.

Wider Implications for Healthcare

This innovative technology poses significant advantages for lung cancer screening programs, effectively combining the assessment of coronary artery health with lung health evaluations. Patients undergoing a CT scan for unrelated issues can now also receive valuable information regarding their heart health, allowing for potential early interventions that could save lives.

The introduction of this technology not only streamlines the diagnostic process but also empowers healthcare professionals to act quickly, improving outcomes for patients with undetected cardiac risks.

As Riverain Technologies continues its mission to revolutionize the standards of radiology, the impact of the ClearRead CT CAC could redefine how healthcare professionals approach cardiothoracic health. In a landscape where early diagnosis is crucial, tools like these are paramount to cultivating efficient and pioneering healthcare solutions.

For further insights and demonstrations, attendees can visit the Riverain Technologies booth at the RSNA meeting, specifically set at McCormick Place, South Hall #4523.

About Riverain Technologies

Dedicated to redefining the cardiothoracic diagnostic landscape, Riverain Technologies aims to eliminate delays in diagnosis while enhancing the accuracy of evaluations. Their commitment to innovation continues to guide efforts toward developing solutions that not only improve workflow efficiencies but also substantially enhance patient outcomes. To learn more about their offerings, visit Riverain Technologies.